Part:BBa_K3994010
PhrpL_amilGFP_IL10_PJ23104_ttrS
promoter
Profile
Name: PhrpL_amilGFP_IL10_PJ23104_ttrS
Base Pairs: 4231 bp
Origin: Synthetic
Properties: A coding sequence of amilGFP and IL10 protein.
Usage and Biology
Background
nflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease of unknown etiology, including ulcerative colitis (CD) and Crohn’s disease (CD). This chronic disease, which is prone to repeated deterioration, currently lacks unified diagnostic and treatment standards, and is posing a great threat to public health. Drug therapy (anti-inflammatory drugs) is the preferred treatment for IBD. However, studies in the past 10 years have found that 30-50% of IBD patients do not respond to anti-TNF treatment. In addition, after long-term use of anti-inflammatory drugs, the patient's intestinal microbial status changes over time, and the effect may be lost due to drug resistance. Therefore, we need to seek help from other treatments for IBD.
Construct design
This part is a coding sequence of amilGFP and IL10. amilGFP is a fluorescent protein. IL10 is an anti-inflammatory factor. These two factors were under PhrpL promoter. And this part is inserted into plasmid.
BBa_K3994005
Name: PhrpL
Base Pairs: 190bp
Origin: Synthetic
Properties: A coding sequence of promoter hrpL.
Usage and Biology
It is the sequence of inducible promoter PhrpL. HrpR protein binds to HrpS protein forming a complex and then triggering the transcription of induced promoter PhrpL. It functions like a AND logic gate to open a gene circuit. The hrpL promoter (PhrpL) contains a functional UAS relative to the transcription start-site, to which purified HrpR, HrpS and HrpRS bind in electrophoretic mobility shift assays.
BBa_K3994006
Name: IL10
Base Pairs: 864bp
Origin: Homo sapiens, genome
Properties: A coding sequence of an immune regulatory cytokine
Usage and Biology
This is a coding sequence of IL10. This is a major immune regulatory cytokine that acts on many cells of the immune system where it has profound anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation.
Proof of function
Attempt 1
Sample 1: NO3- + S4O62-
Sample 2: S4O62-
Sample 3: NO3-
Sample 4: Blank Control
As shown above, there is obvious fluorescence in sample 1 and sample 2; for sample 3 and sample 4, there also a slight fluorescence produced in the tubes. In order to scientifically quantify the result, we used ELIASA to read the accurate fluorescence intensity, respectively.
According to the histogram above, we can see that Sample 1 (NO3-+ S4O62-) presents obvious higher fluorescence intensity than the rest three samples which means our design working. But we do realize that Sample 2 (S4O62-) also presents fluorescence than the blank control which confused us a lot. According to our design, if we only add S4O62- without NO3-, this AND gate wouldn’t allow to pass into the reporter (Part 3) as there is a closed door of the NO3- sensor (Part 1). Therefore, we thought there was something wrong in Part 1.
In order to figure out the reason, we did several literature research and find out that in Part 1 we didn’t build the NarX-NarL two-component regulator (Figure 5), which shall be the first one to sense nitrate and that is why Part 1 didn’t work fine as we expected.
Ref. Woo, Seung-Gyun, et al. "A designed whole-cell biosensor for live diagnosis of gut inflammation through nitrate sensing." Biosensors and Bioelectronics 168 (2020): 112523.
Attempt 2
Sample 1: Negative Control (E. coli)
Sample 2: Positive Control (E. coli/amilGFP)
Sample 3: E. coli/pUC-57_Part 3
Sample 4: E.coli/pSU2718-Part 1_Part 2+pUC-57_Part 3
In order to further analyze the performance of Part 2, we also designed the control groups as showing above where Sample 1 and Sample 2 were presented as the comparison of the fluorescence phenomenon. We can see that there was no fluorescence in Sample 3 (the report part, Part 3). According to the result of Sample 3 and Sample 4 (Figure 6), we could infer that the AND gate design works (HrpR_HrpS, PhrpL) as the Part 3 didn’t respond when there is no Part 1 and Part 2.
Of course, we also repeated the experiments and measured the fluorescence intensity by ELIASA. The data is given below.
According to the trend in Figure 8, the fluorescence intensity of pUC57-Part 3 presents the similar level as that of blank control and group NO3-, which means the “gate keeper” promoter, PhrpL works well and this conclusion also back up the conclusion that the AND gate design works well (HrpR_HrpS, PhrpL).
As the group S4O62 did present higher fluorescence intensity than that of group NO3- whenever OD600 equals to 0.8 or 1, it indicates that Part 2 and Part 3 both works well as Part 2 did show “green light” to the thiosulfate to finally “light” the Part 3.
References
1 CDC -What is inflammatory bowel disease, available at: https://www.cdc.gov/ibd/what-is-ibd.htm
2炎症性肠病 百度百科available at: https://baike.baidu.com/item/%E7%82%8E%E6%80%A7%E8%82%A0%E7%97%85/5296499?fr=aladdin
3 Data and Statistics ====Inflammatory Bowel Disease (IBD) in the United StatesAvailable at: https://www.cdc.gov/ibd/data-statistics.htm
4. Wang, Baojun, et al. "Engineering modular and orthogonal genetic logic gates for robust digital-like synthetic biology." Nature communications 2.1 (2011): 1-9.
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal XbaI site found at 25
Illegal XbaI site found at 175
Illegal PstI site found at 13 - 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 2233
Illegal NheI site found at 2256
Illegal PstI site found at 13 - 21INCOMPATIBLE WITH RFC[21]Illegal BamHI site found at 31
- 23INCOMPATIBLE WITH RFC[23]Illegal XbaI site found at 25
Illegal XbaI site found at 175
Illegal PstI site found at 13 - 25INCOMPATIBLE WITH RFC[25]Illegal XbaI site found at 25
Illegal XbaI site found at 175
Illegal PstI site found at 13
Illegal AgeI site found at 379 - 1000COMPATIBLE WITH RFC[1000]
None |